YALE PHYLLIS R 4

What Happened
Phyllis R. Yale, a director of Bristol Myers Squibb Co. (BMY), was granted 577.082 deferred share units on 2026-03-31 valued at $60.65 each for a total reported value of $35,000. The transaction is reported as an award/acquisition (derivative), not an open-market purchase.

Key Details

• Transaction date: 2026-03-31; Form 4 filed: 2026-04-02.
• Transaction type/code: A (award/acquisition) — derivative grant of Deferred Share Units.
• Quantity/price/value: 577.082 units @ $60.65 each = $35,000.
• Footnote F1: Each Deferred Share Unit converts into one share of common stock upon settlement; units become settleable when the director leaves the board or at a previously specified future date.
• Footnote F2: Grant includes amounts under the 1987 Deferred Compensation Plan for Non-Employee Directors and reinvested dividends.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Timeliness: The Form 4 was filed two days after the transaction date (appears to be timely).

Context
This was a compensation award for a non-employee director (deferred share units) rather than a market buy or sale. Deferred share units are a common way to compensate directors and only convert into actual shares upon settlement, so they do not represent an immediate open-market purchase or sale.